BUZZ - JPMorgan upgrades Biogen rating to "Overweight", stock price rises

October 12 - ** The share price of pharmaceutical company Biogen (BIIB.O) rose nearly 2% in pre-market trading to $230.35

** JPMorgan upgraded the stock from “Neutral” to “Overweight”; the price target was raised from $210 to $300, representing approximately 33% upside from last Friday’s closing price

** The brokerage believes that several key catalysts will emerge in 2027, including felzartamab for antibody-mediated rejection (AMR) in organ transplantation, with a potential market size in this field exceeding $2 billion

** “We believe that, as the company is no longer just a Leqembi single-story, BIIB will become one of the most attractive investment stocks in 2027.” (This drug is used to treat Alzheimer’s disease)

** On average, 38 analysts rate the stock as a “Buy”; the median price target is $242 — data compiled by LSEG

** As of the previous trading day’s close, the stock had gained 28.25% year-to-date

(To facilitate non-English-speaking users, Reuters provides automated translation of its reports into several other languages. As automated translations may be inaccurate or lack the required context, Reuters does not guarantee the accuracy of the automated translation, which is provided for readers’ convenience only. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation services.)